22912-31-8

Usage

Uses

Used in Pharmaceutical Industry:
1-(Dimethylamino)cyclopentanecarbonitrile is used as a building block for the synthesis of various pharmaceuticals due to its ability to contribute to the formation of complex molecular structures that can exhibit therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(dimethylamino)cyclopentanecarbonitrile is utilized as a precursor in the development of compounds that can protect crops from pests and diseases, leveraging its reactivity and structural features to create effective agrochemicals.
Used in Organic Synthesis:
1-(Dimethylamino)cyclopentanecarbonitrile is employed as a reagent in organic synthesis for the preparation of heterocyclic compounds, which are important in various chemical and pharmaceutical applications due to their diverse chemical and biological activities.
Used in the Development of New Drug Molecules:
1-(dimethylamino)cyclopentanecarbonitrile is used as a key intermediate in the research and development of novel drug molecules, where its unique structure can be manipulated to create new pharmaceutical entities with potential therapeutic benefits.
Used in the Production of Fine Chemicals and Specialty Materials:
1-(Dimethylamino)cyclopentanecarbonitrile also serves as a precursor in the creation of fine chemicals and specialty materials, where its specific structural attributes are harnessed to produce high-value products for various applications.

InChI:InChI=1/C8H14N2/c1-10(2)8(7-9)5-3-4-6-8/h3-6H2,1-2H3

Upstream product

• 151-50-8 potassium cyanide 
• 124-40-3 dimethyl amine 
• 120-92-3 cyclopentanone 
• 5117-85-1 1-hydroxycyclopentanecarbonitrile 
• 506-59-2 N,N-dimethylammonium chloride 

Downstream Products

• 164642-21-1 1-(aminomethyl)-N,N-dimethylcyclopentane-1-amine 
• 895589-79-4 (+/-)-{1-[amino(phenyl)methy|]cyclopentyl}dimethylamine 
• 895632-66-3 C₁₄H₁₉FN₂ 
• 895632-64-1 C₁₅H₂₂N₂O 
• 22912-22-7 α-(1-Dimethylamino-cyclopentyl)-benzylalkohol 
• 22912-16-9 1-(Dimethylamino-cyclopentyl)-phenyl-keton 

Relevant academic research and scientific papers

COMPOUNDS HAVING ACTIVITY AT THE GLYCINE TRANSPORTER GLYT1 AND USES THEREOF

The present invention relates to compounds of formula (I), salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. Th

GLYCINE TRANSPORTER INHIBITING COMPOUNDS AND USES IN MEDICINE

Compounds of formula (I) and salts and solvates thereof are provided: wherein either 1 ) R1, R2, R3 and R4 and all methyl, or 2) R1 and R2 form a pyrrolidinyl group and R3 and R4 are both methyl, or 3) R1 and R2 are both methyl and R3 and R4 together form

GLYCINE TRANSPORTER INHIBITING COMPOUNDS AND USES IN MEDICINE

N-[[1-dimethylaminojcyclopentyl](phenyl)methyl]-4-fluoro-2-methyl-6- (methyloxy)benzamide:and salts and solvates thereof are provided. Uses in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, such as psychoses, deme

2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES

The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof. Formula (I) wherein R1 is a group selected from: Formulas (A), (B), (C)

OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS

The present invention relates to compounds of formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

Radiosynthesis of 3-(3-[18F]fluoropropoxy)-4-(benzyloxy)-N-[(1- dimethylaminocyclopentyl)methyl]-5-methoxybenzamide, a potential PET radiotracer for the glycine transporter GlyT-2

The recently described selective and potent GlyT2 antagonist, 4-benzyloxy-3, 5-dimethoxy-N-[(1-dimethylaminocyclopentyl) methyl]benzamide (IC50 = 16 nM) provided an important additional tool to further characterize GlyT2 pharmacology. In order to identify an effective PET radioligand for in vivo assessment of the GlyT-2 transporter, 3-(3-[ 18F]fluoropropoxy)-4-(benzyloxy)-N-((1-dimethylaminocyclopentyl) methyl)-5-methoxybenzamide ([18F]3), a novel analog of 4-benzyloxy-3,5-dimethoxy-N-[(1-dimethylaminocyclopentyl) methyl]benzamide was synthesized using a one-pot, two-step method. The NCA radiofluorination of 1,3-propanediol di-p-tosylate in the presence of K2CO3 and Kryptofix-222 in acetonitrile gave 81% 3-[18F]fluoropropyl tosylate, which was subsequently coupled with 4-benzyloxy-3-hydroxy-5-methoxy-N-[(1- dimethylaminocyclopentyl) methyl]-benzamide in the same reaction vessel. Solvent extraction and HPLC (Eclipse XDB-C8 column, 80/20/0.1 MeOH/H 2O/Et3N, 3.0 ml/min) gave [18F]3 in 98.5% radiochemical purity. The radiochemical yield was determined to be 14.0-16.2% at EOS, and the specific activity was 1462 ± 342 GBq/μmol. The time of synthesis and purification was 128 min. The final product was prepared as a sterile saline solution suitable for in vivo use. Copyright

Serotoninergic properties of new conformationally restricted benzamides

A new series of benzamides derived from metoclopramide have been synthesized, in which the vicinal carbon of the basic nitrogen atom of the ethyl chain is situated on the C3, C4, C5 and C6 rings. The diamino derivatives were prepared through Strecker's reaction from the corresponding ketones except for the cyclopropyl derivatives where 1-ethoxy-1-trimethylsiloxy cyclopropane was used as the starting material. The benzamides were prepared using the mixed anhydride method. They were tested in binding assays for D2, 5-HT3 and 5-HT4 receptors. The results show a marked increase in the selectivity and potency of these derivatives for 5-HT3 receptors with regard to metoclopramide (compound 1d: 5-HT3 K(i) = 9.03 nM; 5-HT4 K(i) > 5000; D2 K(i) > 5000). The influences of steric hindrance and hydrophobic properties on the affinity of benzamide derivatives for 5-HT3 receptors were also emphasized by these data. The X-ray crystal structure of compound 1d was compared with that of the minimal energy conformer of BRL 24682, a reference 5-HT3 receptor antagonist benzamide, determined using the Random Search program. Superimposition of the two structures showed a suitable fit between the pharmacophore groups previously determined to be important for 5-HT3 receptor antagonists. On the other hand, the hydrophobic parts of the basic moieties had different spatial occupancies.

Addition of diphenylphosphine to Michael-type olefins: the preparation of phosphine-nitrile and phosphine-ester ligands

The reactions of five Michael-type olefins with diphenylphosphine have been carried out. 1-Cyanocyclopentene, 1-cyanocyclohexene, and 4-t-butyl-1-cyanocyclohexene all provide the corresponding 2-diphenylphosphino-1-cyanocycloalkanes, and both methyl acrylate and ethyl methacrylate yield to corresponding 2-diphenylphosphinopropionates.For the products from 1-cyanocyclopentene and 1-cyanocyclohexene, 13C and 31P NMR data are consistent with the formation of both trans (Ph2P equatorial and CN axial) and cis (both Ph2P and CN equatorial) isomers.The morpholine amide of 3-diphenylphosphinopropionic acid has been obtained by treatment of methyl-3-diphenylphosphinopropionate with the dimethylaluminum adduct of morpholine.This phosphine, Ph2Pmorph, has been isolated as its palladium(II) complex, (Ph2Pmorph)2PdCl2.A phosphine-benzaldimine, Ph2P(CH2)3NC(H)C6H5, has been obtained by reacting Ph2P(CH2)3NH2, from the reduction of PhP(CH2)2CN, with benzaldehyde in the presence of molecular sieves.